Background: This study investigates the prognostic value of metabolic tumor burden calculated using dual-time-point 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)/CT in patients with locally advanced cancer. Methods: This study examines 42 patients (35 men and 7 women, 38-73 years old) with locally advanced oropharyngeal or hypopharyngeal cancer who had undergone FDG-PET/CT before receiving chemoradiotherapy. Maximum standardized uptake value (SUV max ), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured for the early and delayed phases. Statistical analyses included receiver operating characteristic curve, univariate and multivariate analysis. Results: ΔSUV max , both phases of MTV 2.5 and TLG 2.5 , early TLG 40% , ΔTLG 2.5 , and ΔTLG 40% were significantly associated with progression-free survival (PFS). In multivariate analysis, early TLG 2.5 (P = .005) was an independent prognostic factor of PFS. Conclusion: Not the percent change but the value calculated in the early phase in several parameters using dual-time-point FDG-PET/CT is significantly associated with the outcomes of patients with locally advanced oropharyngeal or hypopharyngeal cancer.
| INTRODUCTION
Many cases of oropharyngeal and hypopharyngeal cancer are diagnosed as advanced cancer before initial treatment; therefore, chemoradiotherapy (CRT) is often chosen as the first-line treatment. [1] [2] [3] [4] 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT is not only useful for staging [5] [6] [7] [8] [9] but can also be used to evaluate the treatment effects and to predict patient outcome. [10] [11] [12] [13] According to some previous studies that evaluated dualtime-point FDG-PET/CT, malignant tumors generally exhibit enhanced FDG uptake during the delayed phase, compared with the early phase. [14] [15] [16] In contrast, physiological FDG uptake is known to decrease over time after FDG injection. 15 Thus, FDG-PET/CT images obtained during the delayed phase are considered to reflect the distribution of tumor cells
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Statistical analyses were performed by Hirofumi Kuwabara. more accurately than those obtained during the early phase. However, some previous studies showed that the percentage variation of the standardized uptake values (SUVs) between early and delayed phases (retention index) was useful for distinguishing between malignant and benign lesions. 8, 17 Furthermore, some studies showed that retention index was a prognostic factor of survival for patients with cancer. 8, 18 Given these results, we hypothesized that dual-time-point FDG-PET/CT is more likely to reflect the natures of malignant tumors than a single-phase study. Recently, metabolic tumor burden, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG), which reflects both tumor volume and glycolysis, have been widely used and reported in FDG-PET/CT studies. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] However, in most previous studies, metabolic tumor burden obtained from a single-phase study has been used, and a few studies have applied such parameters calculated using a dual-time-point study. 21, 29 In this study, we examined whether the metabolic tumor burden obtained using dual-time-point FDG-PET/CT can be available for predicting the outcomes of patients with locally advanced oropharyngeal or hypopharyngeal cancer.
| PATIENTS AND METHODS

| Patients
We extracted the medical records of 112 consecutive patients with locally advanced oropharyngeal or hypopharyngeal cancer who underwent dual-time-point FDG-PET/CT before initial treatment at our hospital between January 1, 2007, and December 31, 2013 . The inclusion and exclusion criteria are presented in Figure 1 . This retrospective study was approved by the Ethics Committee for Clinical Research (approved number: M2016-051). Written informed consent was waived.
| FDG-PET/CT protocol
Patients fasted for at least 4 hours before the injection of FDG (3.7 MBq/kg body weight, mean of 244.6 MBq, range, 157-339 MBq). All patients drank approximately 300 mL of water as oral hydration after the FDG injection. Dual-timepoint FDG-PET/CT imaging was performed using a PET/CT scanner (Aquiduo; Toshiba, Japan) in all cases with the same method. The early and delayed phases of head and neck imaging were performed at 63 minutes (range, 60-76 minutes) and 131 minutes (range, 114-148 minutes) after FDG injection, respectively. CT studies for attenuation correction were performed under free breathing with the following parameters: 120 LV, 150 mA, field of view 500 mm, pitch 15.0, and slice thickness 2.0 mm. PET emission data were obtained in 3D mode with the following parameters: 4 minutes per bed position (for 8 minutes in all), matrix size 256 × 256, and Gaussian filter size 5 mm. Although whole-body imaging was also performed at 76 minutes (range, 70-98 minutes), these data were used for only excluding patients with distant metastases.
| Image analysis
All images were analyzed by a nuclear medicine physician and a radiation oncologist. Globular volumes of interest (VOIs) were placed on each area corresponding to primary lesion and lymph node metastases. We excluded FDG uptake outside the lesion (such as physiological uptake) from each VOI as much as possible. Cervical lymph node metastases were defined using the criteria reported by Nakamura et al. 9 The maximum standardized uptake value (SUV max ), MTV, and TLG were calculated for all lesions for both the early and delayed phases. The cutoff SUVs for calculating MTV and TLG were defined as 2.5% and 40% of the SUV max , respectively, based on the results of previous reports. [19] [20] [21] [22] MTV was defined as the summed volume of the voxels whose SUV was higher than the cutoff value in 
| Statistical analysis
We defined progression-free survival (PFS) and overall survival (OS) as primary and secondary end points, respectively. We used the Kaplan-Meier method to estimate the PFS and OS. The value measured in the delayed phase and Δ of each parameter was applied for statistical analyses. First, we calculated the cutoff value for each parameter for univariate analysis using receiver operating characteristic (ROC) curves. These curves were plotted to determine whether the investigated parameters were capable of discriminating good responders to CRT. We judged patients as good responders according to the following criteria: (1) otolaryngologists judged that primary and metastatic lesions had disappeared after CRT according to medical examination including laryngoscopy, palpation, and ultrasonography, (2) complete response was confirmed by pathological findings or RECIST1.1 criteria, and (3) disease progression was not observed by at least a 6-month follow-up after completion of CRT. Thereafter, as a univariate analysis, we compared differences in PFS and OS between the 2 groups divided by each cutoff value using the log-rank test. Finally, the Cox hazard proportional model was used for the multivariate analysis to determine whether any parameter can predict survival. After examining the collinearity of each parameter, a multivariate analysis was performed using all parameters except those with extremely high collinearity. Among collinear parameters, the one with the highest correct diagnostic rate was used for multivariate analysis, in accordance with a previous study. 21 A two-sided P-value <.05 was considered statistically significant.
| RESULTS
According to exclusion criteria, 38 patients were excluded from the population of 112 patients. Thereafter, 42 patients who satisfied inclusion criterion of uniform therapeutic strategy were extracted ( Figure 1 ). The clinical characteristics of these 42 patients are listed in Table 1 . The blood glucose value immediately before FDG injection was 106 mg/dL (range, 82-151 mg/dL). We checked the wholebody PET/CT imaging before initial treatment and confirmed no distant metastasis in all patients. The results of the ROC curve analysis are summarized in Table 2 . The ROC curve analysis showed that ΔSUV max had a relatively high diagnostic accuracy (>70%). The results of the univariate and multivariate analyses of PET/CT parameters are summarized in Tables 3 and 4 . The 2-and 5-year PFS rates were 69.0% and 64.2%, respectively. ΔSUV max , early and delayed MTV 2.5 , early and delayed TLG 2.5 , ΔTLG 2.5 , early TLG 40% , and ΔTLG 40% were significantly associated with PFS (P < .05). Furthermore, a multivariate analysis revealed that early TLG 2.5 was an independent prognostic factor for PFS (hazard ratio = 5.784, P = .005). Figure 3 shows Kaplan-Meier curves of PFS of the 2 groups separated by early TLG 2.5 (cutoff, 195 g; P = .001, log-rank test). The 2-and 5-year OS rates were 90.5% and 84.3%, respectively. Although some parameters were significantly associated with OS (P < .05), no independent prognostic factors for OS were confirmed in a multivariate analysis.
| DISCUSSION
In this study, we evaluated the prognostic value of metabolic tumor burden calculated using dual-time-point FDG-PET/ CT in patients with advanced oropharyngeal or hypopharyngeal cancer.
Like the results of previous studies, [14] [15] [16] almost all lesions showed higher FDG uptakes during the delayed phase, compared to the early phase, in our study. Not SUV max but ΔSUV max was significantly associated with both PFS and OS in a univariate analysis. Changes in the behavior of FDG uptake between the 2 different phases might reflect the nature of these malignant tumors more accurately than the results of a single-phase study. However, SUV max is problematic in that it represents only the maximum SUV in the lesion. Therefore, the concept of metabolic tumor burden, such as MTV and TLG, has been introduced to consider both FDG uptake and tumor volume. In this study, MTV 2.5 and TLG 2.5 differed significantly with respect to PFS and OS, like the results of previous studies. 19, 22 In addition, we examined whether the changing rate of MTV and TLG, which were not used in those studies, can predict patient survival. Although no significant differences were observed in ΔMTV 40% , the ΔTLG 40% was significantly different in this study. However, ΔMTV 2.5 and ΔTLG 2.5 could not be used to predict survival. When using an absolute cutoff value (SUV = 2.5, in this case) to calculate MTV and TLG, there are few benefits to performing dual-time-point FDG-PET/CT. Our study revealed that ΔTLG 40% is significantly associated with PFS. In contrast, Abgral et al. reported that both ΔMTV 40% and ΔTLG 40% are not significantly associated with recurrence-free survival. 21 We speculate that this discordance arose from differences in patient status. For example, in the study reported by Abgral et al., 24% of the enrolled patients had stage I or II disease, for which surgery can be applied as a treatment strategy, whereas 53% of them had stage IV disease, which is generally treated with CRT. However, our study included only patients with advanced-stage cancer to allow a unified therapeutic strategy. In univariate analysis, changing rate of some parameters showed significant differences in PFS. However, they were not identified as independent prognostic factors in multivariate analysis. Dual-time-point FDG-PET/CT is useful for staging and differentiation between benign and malignant lesion but may not be essential for the prognostication of patients with locally advanced oropharyngeal or hypopharyngeal cancer. In the other previous study, Kim et al. evaluated prognostic values of dual-timepoint FDG-PET/CT in patients with non-small-cell lung cancer. They also suggested that SUV max in the early phase has better prognostic value rather than the percent change of SUV. 30 Further studies enrolling patients with some specific cancers might emphasize the importance of PET/CT parameters in the early phase for predicting prognosis, compared to the percent change in a dual-time-point study.
Compared with MTV 2.5 and TLG 2.5 , MTV 40% and TLG 40% do not always increase from the early to the delayed phase because the cutoff value depends on the SUV max . When calculating ΔMTV 40% and ΔTLG 40% , voxels for which the percent change in the SUV did not exceed that of the SUV max are excluded. Considering these characteristics, ΔMTV 40% and ΔTLG 40% may better reflect aspects of tumor nature not limited to tumor volume or glycolysis as estimated using conventional single-phase FDG-PET/CT. Further correlative studies of radiology and pathology are warranted to identify some relationship between the changing rates of PET-based parameters and pathological characteristics.
Attempts to use metabolic tumor burden for not only survival analyses [26] [27] [28] [29] but also radiotherapy planning have been 32 In this study, TLG produced statistically significant results in a survival analysis, and its application to radiotherapy planning is anticipated. The higher ΔTLG 40% showed a higher rate of both local and distant recurrence, enabling more powerful treatments to be chosen, such as a dose escalation technique for the primary lesion with intensity-modulated radiation therapy or the strengthening of systemic chemotherapy. This study had several limitations. First, the patients' medical records were extracted using a sample-sifting process, and all the patients received the same initial treatment, possibly causing a selection bias. Second, not all the lymph nodes were checked pathologically to determine whether each lymph node contained a definite metastasis. Among the lymph nodes included in this analysis, some might not have contained an actual metastasis. Third, the HPV status of the patients was unknown and could not be included in the present analysis because of the retrospective nature of the data. Forth, although MTV and TLG in the VOIs were automatically calculated, the system of our available workstation did not allow modifying original globular VOIs.
In conclusion, not the percent change but the value calculated in the early phase in several parameters using dualtime-point FDG-PET/CT are significantly associated with the outcomes of patients with locally advanced oropharyngeal or hypopharyngeal cancer.
